LRRK2 Antibody (133AT1218): sc-130159

LRRK2 Antibody (133AT1218) is a mouse monoclonal IgG1 kappa light chain antibody that detects LRRK2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-LRRK2 antibody (133AT1218) is available as a non-conjugated format, providing researchers with a reliable tool for studying this critical protein. LRRK2 plays a significant role in neuronal signaling and is implicated in the pathogenesis of Parkinson′s disease, a neurodegenerative disorder characterized by the degeneration of dopaminergic neurons and the presence of Lewy bodies. These Lewy bodies are aggregates of misfolded proteins that disrupt cellular function, leading to the hallmark symptoms of the disease. LRRK2 is primarily localized in the cytoplasm and is associated with various cellular membrane structures, which is crucial for its function in signaling pathways that regulate neuronal health and survival. LRRK2′s structure includes multiple functional domains, such as a GTPase domain and a kinase domain, which are essential for enzymatic activity and interactions with other proteins. Notably, LRRK2 has been shown to interact with several key proteins involved in synaptic function and neuroinflammation, highlighting its importance in maintaining neuronal integrity and potential as a therapeutic target in Parkinson′s disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LRRK2 Antibody (133AT1218) References:

1. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.  |  Zimprich, A., et al. 2004. Neuron. 44: 601-7. PMID: 15541309
2. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.  |  Nichols, WC., et al. Lancet. 365: 410-2. PMID: 15680455
3. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.  |  Di Fonzo, A., et al. Lancet. 365: 412-5. PMID: 15680456
4. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.  |  Kachergus, J., et al. 2005. Am J Hum Genet. 76: 672-80. PMID: 15726496
5. Genetics of Parkinson's disease.  |  Gasser, T. 2005. Curr Opin Neurol. 18: 363-9. PMID: 16003110
6. Genetics of Parkinson's disease.  |  Morris, HR. 2005. Ann Med. 37: 86-96. PMID: 16026116
7. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.  |  Adams, JR., et al. 2005. Brain. 128: 2777-85. PMID: 16081470
8. LRRK2 mutations are not common in Alzheimer's disease.  |  Toft, M., et al. 2005. Mech Ageing Dev. 126: 1201-5. PMID: 16087219
9. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease.  |  Bialecka, M., et al. 2005. Neurosci Lett. 390: 1-3. PMID: 16115731
10. Genetics of parkinsonism.  |  Lewthwaite, AJ. and Nicholl, DJ. 2005. Curr Neurol Neurosci Rep. 5: 397-404. PMID: 16131423
11. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century.  |  Lesage, S., et al. 2005. Am J Hum Genet. 77: 330-2. PMID: 16145815
12. LRRK2: both a cause and a risk factor for Parkinson disease?  |  Foroud, T. 2005. Neurology. 65: 664-5. PMID: 16157895
13. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.  |  Paisán-Ruíz, C., et al. 2005. Neurology. 65: 696-700. PMID: 16157901
14. LRRK2 mutations in Parkinson disease.  |  Farrer, M., et al. 2005. Neurology. 65: 738-40. PMID: 16157908
15. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations.  |  Zabetian, CP., et al. 2005. Neurology. 65: 741-4. PMID: 16157909
16. Lrrk2 pathogenic substitutions in Parkinson's disease.  |  Mata, IF., et al. 2005. Neurogenetics. 6: 171-7. PMID: 16172858
17. Genetics of Parkinson's disease.  |  Bonifati, V. 2005. Minerva Med. 96: 175-86. PMID: 16175160